New trial will send drug to COVID-19 patients' home to see if it can prevent serious complications

A new international clinical trial will examine if colchicine, a drug most often used to treat gout, can can reduce rates of hospitalization and death caused by the novel coronavirus.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Cardiol J. 2021 Oct 13. doi: 10.5603/CJ.a2021.0123. Online ahead of print.ABSTRACTColchicine is an effective anti-inflammatory agent used to treat gout, coronary artery disease, viral pericarditis, and familial Mediterranean fever. It has been found to act by preventing the polymerization of the protein called tubulin, thus inhibiting inflammasome activation, proinflammatory chemokines, and cellular adhesion molecules. Accumulating evidence suggests that some patients with coronavirus disease 2019 (COVID-19) suffer from "cytokine storm" syndrome. The ideal anti-inflammatory in this setting would be one that is re...
Source: Cardiology Journal - Category: Cardiology Authors: Source Type: research
AbstractCurrent data demonstrated that severe cases of coronavirus-disease-19 (COVID-19) require treatment with antiviral therapy, dexamethasone, supportive care, as well as some anti-rheumatic drugs, among them, cytokine inhibitors and colchicine. Colchicine is an anti-inflammatory drug that is being used in rheumatology for many years to treat mostly gout, calcium pyrophosphate deposition disease, and Familial Mediterranean Fever. Here, we present for the first time, two patients suffering from gout being treated with colchicine, who were affected from severe acute respiratory coronavirus-2 (SARS-CoV-2) syndrome. Both pa...
Source: Rheumatology International - Category: Rheumatology Source Type: research
chvoerer Guillemin The World Health Organisation recommends monitoring the circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated anti–SARS-CoV-2 total immunoglobulin (IgT) antibody seroprevalence and in vitro sero-neutralization in Nancy, France, in spring 2020. Individuals were randomly sampled from electoral lists and invited with household members over 5 years old to be tested for anti–SARS-CoV-2 (IgT, i.e., IgA/IgG/IgM) antibodies by ELISA (Bio-rad); the sero-neutralization activity was evaluated on Vero CCL-81 cells. Among 2006 individuals, the raw seroprevalen...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Early identification of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection enables rapid isolation to prevent transmission (European Centre for Disease Prevention and Control, National Institutes of Health, 2020, The World Health Organization). Symptoms of coronavirus disease 2019 (COVID-19) are common to a range of respiratory pathogens; therefore, accurate diagnostics are required for differential diagnosis.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
Brazilian researchers found colchicine, which is used to treat gout, helped reduce the need for oxygen therapy by more than a third in hospital coronavirus cases in a 75-patient study.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Authors: Hase R, Kurata R, Ishida K, Kurita T, Muranaka E, Mito H Abstract A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
There comes a day in every woman ’s life when she must wonder: Where on earth have everyone’s manners gone? This phase of life, I once believed, was the same phase when I would shout things like: “You kids get off my lawn!” “Oh, it’s just a touch of gout!” And so on. Is it my […]Find jobs at  Careers by  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Physician COVID-19 coronavirus Infectious Disease Source Type: blogs
A new study from the University of Athens in Greece found that 14% of coronavirus patients in a control group died compared to 1.8% in the group receiving colchicine, an old gout drug.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Abstract In light of the recent pandemic, favipiravir (Avigan®), a purine nucleic acid analog and antiviral agent approved for use in influenza in Japan, is being studied for the treatment of coronavirus disease 2019 (COVID-19). Increase in blood uric acid level is a frequent side effect of favipiravir. Here, we discussed the mechanism of blood uric acid elevation during favipiravir treatment. Favipiravir is metabolized to an inactive metabolite M1 by aldehyde oxidase and xanthine oxidase, and excreted into urine. In the kidney, uric acid handling is regulated by the balance of reabsorption and tubular secreti...
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
The search for existing drugs that may help treat coronavirus infections now has researchers testing the heartburn drug Pepcid, among others.
Source: L.A. Times - Health - Category: Consumer Health News Authors: Source Type: news
More News: Clinical Trials | Colchicine | Colcrys | Coronavirus | COVID-19 | Gout | Health